Why Shares of Amyris Are Getting Crushed Today

Failing to deliver on both the top and bottom lines, synthetic-biology specialist Amyris (NASDAQ: AMRS) reported disappointing third-quarter 2021 earnings results yesterday after the market closed. Whereas analysts were expecting the company to report revenue of $80.6 million and breakeven on an earnings-per-share (EPS) basis, the company reported sales and EPS of $47.9 million and negative $0.27, respectively.

In addition, investors are selling shares after learning that the company is raising capital through the issuance of senior convertible notes.

As of 1:38 p.m. EST, shares of Amyris are down 30.2%

Continue reading

Source Fool.com